ADORA2A and neoplasm: Pharmacological blockade of A2AR by selective antagonists decreased tumor growth in a head and neck squamous cell carcinoma mouse model by reducing the population of Tregs inside the tumor, spleen, blood, and lymph node, and enhanced the anti-tumor response of CD8+ T cells by increasing the release of IFN-γ [56].